| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Fair value - mark to market adjustment | - | - | 855 | |
| Net loss available to common stockholders | -32,010 | -14,213 | -78,776 | |
| Net loss per common share, basic | -3.59 | -0.23 | -19.28 | |
| Net loss per common share, diluted | -3.59 | -0.23 | -19.28 | |
| Weighted average common shares outstanding, basic | 8,922,792 | 62,122,283 | 4,085,132 | |
| Weighted average common shares outstanding, diluted | 8,922,792 | 62,122,283 | 4,085,132 | |
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)